Back to search

Article

Empagliflozin and Dapagliflozin in Improving Ejection Fraction: A Prospective Observational Comparison of Clinical Outcomes and Patient Reported Quality of Life

2026-04-02

Abstract excerpt

<title>Abstract</title> <p>Background SGLT2 inhibitors have transformed heart failure treatment, especially empagliflozin and dapagliflozin. Although both have proven cardiovascular benefits in clinical trials, there is little data comparing them in real-world settings. This study aims to address that by comparing their effects on heart function, lab tests, echocardiography, and quality of life using routine cli...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
499843b9-e067-5aa8-a547-8880433f2a79
DOI
10.21203/rs.3.rs-9290020/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Empagliflozin and Dapagliflozin in Improving Ejection Fraction: A Prospective Observational Comparison of Clinical Outcomes and Patient Reported Quality of LifeDOI 10.21203/rs.3.rs-9290020/v1
Dapagliflozin vs. empagliflozin in patients with chronic heart failure: a single-center registry analysisSemantic proximity
Ventricular remodeling with dapagliflozin in elderly women with HFpEF--a single center prospective studySemantic proximity
Effect of Beta Blockers on Exercise Capacity, Diastolic Function, and Quality of Life in Patients with Heart Failure with Preserved Ejection Fraction: A Secondary Analysis of INDIE-HFpEF and RELAXSemantic proximity
SGLT2i, ARNi and Diuretic Use in Patients with Heart Failure Among the Preserved and Reduced Ejection Fraction: A Retrospective Observational StudySemantic proximity
Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension.Semantic proximity
Cardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial ancillary study.Semantic proximity
HFpEF as the Predominant and Underrecognized Heart Failure Phenotype in Type 2 Diabetes: Evidence from the DIABET-IC StudySemantic proximity
How Diabetes and Heart Failure Modulate Each Other and Condition Management.Semantic proximity
Cardiovascular drugs approved for heart failure with reduced ejection fraction and/or post-myocardial infarction exert consistent effects in both populations: A meta-analysis and meta-regression of randomized controlled trialsSemantic proximity
Recent advances in the treatment of chronic heart failureSemantic proximity
Real-World Effectiveness of SGLT2 Inhibitors Across Heart Failure Phenotypes: A Meta-Analysis.Semantic proximity
Harnessing the Synergy of SGLT2 Inhibitors and Continuous Ketone Monitoring (CKM) in Managing Heart Failure Among Patients with Type 1 DiabetesSemantic proximity
Select a neighboring publication to make it the new centre.